LXRX— LEXICON PHARMACEUTICALS, INC.

$1.99+18.45%

1 insider bought $723K worth of LXRX in the last 30 days — 6.9x above historical baseline

Velocity Score

6.93x

Current Rate (30d)

5.8K sh/day

Baseline Rate

—

Unique Insiders (30d)

Price Chart

Loading…

Insider Transactions

Sort by

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-02-25	2026-02-27	DEBBANE RAYMOND	Director	Purchase	2,000	$1.49	$3K	1.91M	View ↗
2026-02-23	2026-02-25	DEBBANE RAYMOND	Director	Purchase	100.0K	$1.47	$147K	1.90M	View ↗
2026-02-20	2026-02-23	DEBBANE RAYMOND	Director	Purchase	100.0K	$1.48	$148K	1.80M	View ↗
2026-02-19	2026-02-23	DEBBANE RAYMOND	Director	Purchase	50.0K	$1.44	$72K	1.70M	View ↗
2026-02-18	2026-02-18	DEBBANE RAYMOND	Director	Purchase	133.7K	$1.32	$176K	1.65M	View ↗

1–5 of 7

1 / 2

No recent congressional transactions.

No annual data found.

Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript